Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (November 2011)
37 slides from Fluoropharma Medical's investor presentation, Nov 30, 2011
Slide 1: Enabling Personalized Medicine by Making the Invisible, Visible
Fluoro —— _— Pharma Enabling Personalized Medicine by Making the Invisible, Visible.
Slide 2: Forward-Looking Statements
Forward-Looking Statements — Pharma This presentation contains “forwarclooking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by the
Slide 3: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE HEART IMAGING PROGRAMS CLINICAL BENEFIT PATIENT MANAGEMENT www.FluoroPharma.com Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital Imaging drugs for diagnostic testing BFPET = Myocardial perfu
Slide 4: Investment Highlights
Investment Highlights Pharma Proprietary products that support new technologies for personalized medicine + Next generation / first-in-class diagnostic imaging * Helps determine the course of cardiac treatment Two Phase Il-ready products with short study timelines. both directed to very large market
Slide 5: Radiopharmaceutical value chain players
Radio- Pharmaceutical Distribution IBA Molt Covidien Siemet PETNET Development Multiple players in each value chain www.FluoroPharma.com
Slide 6: Large, Growing Market for Imaging Agents
Large, Growing Market for Imaging Agents — Pharma + Global market expected to exceed $15 billion by 2015 Imaging Drug Market Worldwide Sales Forecast + Fueled by need for personalized medicine . 20 $158 Total + Additional drivers include: * Growing volume of diagnostic examinations and equipment sal
Slide 7: The Next Big Step in Healthcare
Fluoro — The Next Big Step in Healthcare = Pharma MEDICINE TODAY One treatment fits all - =» still a guessing game www.FluoroPharma.com
Slide 8: Personalized Diagnosis
Personalized Diagnosis MEDICINE TOMORROW must be personalized Right Treatment for the Right Patient at the Right Time for the Right Outcome . Before you can see it, Before the patient feels it, We can identify it Personalized medicine begins with the right diagnosis www.FluoroPharma.com
Slide 9: FluoroPharma Enables Personalized Diagnosis
FluoroPharma Enables Personalized Diagnosis = Pharma Imaging provides non-invasive tools with immediate personalized recommendations for treatment Contrast Method Spatial Temporal Resolution + Allows direct visual evaluation of Resolution Resolution disease on a chemical level * Measures the efficac
Slide 10: Market Drivers for New PET Products
Market Drivers for New PET Products — Pharma Growth in PET ural volumes Low capacity Comprehensive adoption of early utilization diagnosis will improve utilization of technology 2000 + Atcapacity, more patients could be diagnosed earlier leading to better patient outcomes jons) 1,740 6 Unutilized 4
Slide 11: PET Imaging Roots are in Oncology
PET Imaging Roots are in Oncology Pharma PET procedures by disease area (by amount tracer) 2500 @ 2000 4 E & f MS Cardiology < 1500 and a » neurology 3 remain EF 4000 strong growth ui opportunities 500 0 2004 2005 2006 2007 2008 2009 Year IH Oncology Mi Neurology ll Cardiology Source: Frost & Sulliv
Slide 12: Cardiovascular Disease is the Next Big Opportunity
Cardiovascular Disease is the Next Big Opportunity Total diagnostic radiopharmaceutical agents market: procedure volume forecasts by imaging procedure (U.S.) - a switch to PET 25. Procedure (millions) 219 20 201 8 20.4 jue (| CAGR 56 j ‘07 -‘09 SPECT (Other) 5.3% 415 SPECT (Cardiac) 7.3% fe PET (Tot
Slide 13: Poised to Capture Cardio Diagnostics
Poised to Capture Cardio Diagnostics = Pharma Cardiovascular Diagnostics PET Molecular Imaging + 1Lin-3 adults havesome form of CV + Superior image quality disease » Large rapidly growing imaging * >40 million CV nuclear scans (MPI) in platform 2009* * Increasing demand for PET * $403 billion: fully
Slide 14: Unmet Need for Better Imaging Methods
Unmet Need for Better Imaging Methods Pharma MRI FDA Warning in 2007 * Nephrogenic systemic fibrosis for Gadolinium-based contrast agents ANATOMICAL FDA Warning in 2007 IMAGING > None of these are a molecular imaging modality (capable of capturing physiology) - FluoroPharma is molecular imaging + De
Slide 15: Making the Invisible, Visible
Fluoro Making the Invisible, Visible ~ Pharma CardioPET VasoPET For ing regions of For detecting cardiovascular blood flow metabolic insufficiency inflamed plaques * For use in combination with + Modified fatty acid (MFA) with an * Avidly taken up by inflammatory stress-testingin patients with inter
Slide 16: BFPET Clinical Use
BFPET Clinical Use — Pharma MYOCARDIAL PERFUSION IMAGING * Evaluate patients with known or suspected CAD for perfusion, wall motion and ejection fraction + Evaluate CAD in patients that are able to exercise CURRENT DIAGNOSTIC TEST * Perfusion imaging with SPECT tracers (MIBI, Tl-201) or Rb-82 CLINIC
Slide 17: BFPET Phase I Trial Findings
BFPET Phase] Trial Findings a Pharma * Rapid extraction from blood * Stable heart uptake overtime * High target to background ratios * Convenientimaging window within 30 minutes of injection + 12 healthy volunteers ages 20-85 + No adverse events * No Clinically significant changes noted in follow-up
Slide 18: The BFPET Opportunity
The BFPET Opportunity Prana Projected BFPET Scans MILLIONS 08 o7 th Est. 5" Year Revenue 06 $209 million 05 Market Est.MktSize Est. Share ee 03 Myocardial perfusion 40 mil. 1% 02 imaging O41 0 Year Year3 Year 5 Peak procedure volume ~0.8 mil. www.FluoroPharma.com
Slide 19: CardioPET Clinical Use
CardioPET Clinical Use — Pharma CARDIAC VIABILITY ASSESSMENT * Identify patients that will benefit from PCI or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT * Invasive coronary angiography CLINICAL NEED + 13 million diagnostic angiography
Slide 20: CardioPET Phase I
CardioPET Phi Fatty acid analog that detects regions of metabolic insufficiency (15 NHV and 6 CAD patients) * CardioPET is safe with no AEs detected * Clinical findings consistent with MPI SPECT * Quality of CardioPET images substantially superior to MPI SPEct A 15 minute scan identifies infarcted t
Slide 21: The CardioPET Opportunity
The CardioPET Opportunity Prana Projected CardioPET Scans MILLIONS Assumption: 09 Est. 5" Year Revenue 08 $230 million 0.7 06 Market Est. Mkt Size Est. Share 05 CAD diagnosis at rest 25 million 15% 04 03 Cardiac viability 4.5 million 40% assessment 0.2 Myocardial perfusion O14 10 million 3% imaging
Slide 22: VasoPET Indications and Clinical Use
VasoPET Indications and Clinical Use Pharma EVALUATION OF * Patients with acute cardiac event or stroke (risk of recurring event) * Therapy following acute cardiac event or stroke (e.g. Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE * Clinical symptoms; several imaging agents in
Slide 23: Detection Of Inflamed Atherosclerotic Plaque
Fluoro Detection Of Inflamed Atherosclerotic Plaque Pharma WHY INFLAMMATION IMAGING? * Diagnosis before symptoms occur * Crucial role at all stages of atherosclerosis * Mayaid drug development DEVELOPMENT STATUS + Preciinical testing completed + IND preparation ongoing * Plan to initiate Phase! proo
Slide 24: The VasoPET Opportunity
The VasoPET Opportunity Prana Projected VasoPET Scans MILLIONS Assumption: 06 Est. 5" Year Revenue 05 $213 million 04 Market Est. Mkt Size Est. Share 03 Sorpening [or 50 million 0.6% atherosclerosis Foll ifter hi 02 ‘ollow-up after heart weritian 98 attack O41 Follow-up after stroke 0.8 million 10%
Slide 25: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction Pharr Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of healthcare M
Slide 26: Experienced Management Team and Advisors
Fluoro Experienced Management Team and Advisors = Pharma Thijs Spoor President, CEO + Healthcare executive with >45 years medical industry experience + Former securities analyst at J.P. Morgan and Credit Suisse covering the medical device and biotechnology industries + Previously led the nuclear car
Slide 27: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones Pharma Capitalize on multiple cardiovascular molecular imaging agents for PET * Cardiac viability assessment * Myocardial perfusion imaging * Inflamed atherosclerotic plaque imaging Address unmet needs in cardiovascular diagnostics by providing + Diagnostic alt
Slide 28: Slide 28
Slide 29: The cycle of classic medicine is reactive medical care
The cycle of classic medicine is reactive medical care Pharma Reactive Medical Care Drug Again Switch Drug Select Drug Disease Severity Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment Personalized Medicine Coalition; Abrahams Presentation www.FluoroPharma.com
Slide 30: Shifting to outcomes focused personalized treatments increases efficiency
Fluc Shifting to outcomes focused personalized treatments increases efficiency Pharma Efficient Medical Care “Right Drug” Disease Severity Diagnosis / Prognosis Diagnosis Health Management; Molecular Screening; Early Detection; Rapid Effective Treatment; Improved Quality of Care Personalized Medicin
Slide 31: Cardiovascular Disease
Cardiovascular Disease Pharma Reactive Medical Care Drug Again Switch Drug Select Drug Disease Severity Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment Personalized Medicine Coalition; Abrahams Presentation www.FluoroPharma.com
Slide 32: Cardiovascular Disease
Cardiovascular Disease — Pharma aa KEY FACTS - US AND WW WHO: “Neglected Global Epidemic + 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. * 1/3 of deaths in China, 42 in Europe + 2.4M deaths US: top cause (38.5%) Malignant Arrhythmias (S High Blood Pressure Coronary Arte
Slide 33: Plaque Imaging
Plaque Imaging Projected Market For Vulnerable Patient Industry www.FluoroPharma.com
Slide 34: AD Statistics
AD Statistics Pharma + Ath leading cause of death after CHD, cancer and stroke. + 25M people estimated to have AD globally (2000). + Incidence - 4.5M globally (2000). * By 2030, 63M people will have AD at current rates. + National cost of AD care is $400B annually in the US. www.FluoroPharma.com AD
Slide 35: Regulatory Strategy
Regulatory Strategy = Pharma US FDA requirements for NDA: safety and efficacy Phase la * Safety, dosimetry and pharmacokinetics: imaging protocol in (Completed) healthy volunteers (15 NHV); single center Phase Ib * Safety, pharmacokinetics and comparison to MPI in small (Completed) number of patient
Slide 36: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints ic pressures PAST FUTURE Fragmen- gy ge » 4 Sd » 4 D4 Integrated, ted. 0 systems of systems of ions by individual st ol ee ate care —— delivery (ul Aligned (1) Conventional (Il) Complex Multistakeholder for Ouleomes Predominant Hep. Medical Groups
Slide 37: Thank you for listening!
Fluoro —— _— Pharma Thank you for listening!
FluoroPharma Medical — Investor Presentation (November 2011) on 6ix